Research programme: clarithromycin nano-emulsion formulation - ADVENTRX PharmaceuticalsAlternative Names: ANX-015; BTH 015; SDP-015
Latest Information Update: 30 Oct 2008
At a glance
- Originator ADVENTRX Pharmaceuticals
- Class Antibacterials; Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Jan 2007 Preclinical development is ongoing